Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 7009

Known as: AZD-7009, AZD7009 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Pharmaceutical regulatory bodies require minimal presence of solvent in an active pharmaceutical ingredient (API) after… Expand
2009
2009
This randomized, double‐blind trial compared cardioversion rates between AZD7009 infusion (15‐minute 3.25 mg/min, 15‐minute 4.4… Expand
Highly Cited
2007
Highly Cited
2007
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major cause of morbidity and… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
AZD7009 (tert-Butyl-2-(7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethylcarbamate) is an… Expand
Highly Cited
2006
Highly Cited
2006
BACKGROUND Acute drug conversion of persistent atrial fibrillation usually fails. OBJECTIVES The purpose of this study was to… Expand
2006
2006
This study evaluated the effects of the novel antiarrhythmic agent AZD7009 on atrial and ventricular repolarization and on the Na… Expand
Highly Cited
2005
Highly Cited
2005
Introduction: AZD7009 is a novel anti‐arrhythmic compound under development for short‐ and long‐term management of atrial… Expand
2005
2005
AZD7009 is a novel antiarrhythmic compound in early clinical development for management of atrial fibrillation… Expand
2005
2005
Background: This study examined the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide. 
Highly Cited
2004
Highly Cited
2004
INTRODUCTION We tested the hypothesis that AZD7009 terminates induced atrial fibrillation (AF) and flutter (AFL) and prevents… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3